Heart rate and death and hospitalization for heart failure in patients with persistent or permanent atrial fibrillation: Insights from the ARISTOTLE trial

Dragos Vinereanu; Daniel M Wojdyla; John H Alexander; Renato D Lopes; Sana M Al-Khatib; Bernard J Gersh; M Cecilia Bahit; Stefan H Hohnloser; Greg C Flaker; Marten Rosenquist; Ziad Hijazi; Lars Wallentin; Christopher B Granger

doi:10.1016/j.ahj.2023.07.006

Heart rate and death and hospitalization for heart failure in patients with persistent or permanent atrial fibrillation: Insights from the ARISTOTLE trial

Am Heart J. 2023 Nov:265:132-136. doi: 10.1016/j.ahj.2023.07.006. Epub 2023 Jul 26.

Affiliations

¹ University of Medicine and Pharmacy Carol Davila, University and Emergency Hospital of Bucharest, Bucharest, Romania. Electronic address: [email protected].
² Duke Clinical Research Institute, Duke University School of Medicine, Durham, NC.
³ Mayo Clinic College of Medicine, Rochester, MN.
⁴ INECO Neurociencias Oroño, Fundación INECO, Rosario, Santa Fe, Argentina.
⁵ JW Goethe University, Frankfurt, Germany.
⁶ University of Missouri, Columbia, MO.
⁷ Karolinska Institute at South Hospital, Stockholm, Sweden.
⁸ Uppsala Clinical Research Center, Uppsala University, Uppsala, Sweden.

PMID: 37506747
DOI: 10.1016/j.ahj.2023.07.006

Abstract

Rate control is fundamental in the treatment of patients with atrial fibrillation (AF). The independent association of heart rate with outcomes and range of heart rate associated with best outcomes remains uncertain. We assessed the relationship between heart rate and clinical outcomes in patients with persistent or permanent AF enrolled in the randomized, double-blind ARISTOTLE trial. In patients with persistent or permanent AF, a faster heart rate is associated with a modest, but statistically significant increase in death and heart failure hospitalizations. TRIAL REGISTRATION: ClinicalTrials.gov (NCT00412984).

Associated data

ClinicalTrials.gov/NCT00412984